Skip to main content

Table 3 Baseline demographic and disease characteristics of patients in PILLAR with and without FSS scores at baseline

From: Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

  With baseline FSS Without baseline FSS
All simeprevir (N = 195) PR (N = 50) All simeprevir (N = 114) PR (N = 27)
Male, n (%) 115 (59.0) 23 (46.0) 59 (51.8) 16 (59.3)
Caucasian race, n (%) 180 (92.3) 49 (98.0) 108 (94.7) 25 (92.6)
Age (range), years 48.0 (18–69) 47.5 (21–61) 42.5 (18–66) 42.0 (21–67)
Body mass index (range), kg/m2† 25.1 (17.1–38.2) 25.7 (17.6–36.0) 24.7 (16.8–39.6) 25.6 (17.5–42.2)
HCV RNA (range) log10 IU/mL 6.6 (3.5–8.1) 6.6 (4.3–7.5) 6.5 (5.1–7.5) 6.2 (5.4–7.1)
HCV RNA >800,000 IU/mL, n (%) 170 (87.2) 43 (86.0) 98 (86.0) 20 (74.1)
HCV genotype, N     
 1a, n (%) 105 (53.8) 21 (42.0) 40 (35.1) 9 (33.3)
 1b, n (%) 88 (45.1) 29 (58.0) 73 (64.0) 18 (66.7)
Metavir score, N     
 F3, n (%) 33 (16.9) 5 (10.0) 13 (11.4) 2 (7.4)
 F4, n (%) 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0)
  1. Median; NS5B sequence-based assay.
  2. PR placebo/peginterferon-α and ribavirin, HCV hepatitis C virus, FSS Fatigue Severity Scale.